InSphero Launches 14 Day Hepatotoxicity Testing Service

Service offers convenient monthly runs at $990 per compound to streamline DILI testing in 3D primary human hepatocytes

As part of our growing portfolio of in-house standardized 3D InSight™ testing services, InSphero has launched a 14 Day Hepatotoxicity Testing Service to simplify DILI testing in patent-pending 3D InSight™ Human Liver Microtissues.  At just $990 per compound, customers receive repeat-dose 14 day toxicity assessment in primary human hepatocyte/Kupffer cell co-culture microtissues, with results returned three weeks after the initial dosing.  IC50 dose-response curves are delivered for the test compound(s) as well as vehicle control and two positive controls (Chlorpromazine and Ketoconazole) using the Promega CellTiter-Glo® Cell Viability Assay (measuring total spheroid ATP content).  Monthly runs initiate on the first Tuesday of every month beginning November 3 and December 1, 2015.   

How will your compounds perform in 3D? 

Click here for details, or contact This email address is being protected from spambots. You need JavaScript enabled to view it. to request a quote or place an order. 

14 day your compound here

InSphero Granted Hanging Drop Patent in United States

Company video